Compare Novo Nordisk A/S (NVO) vs Invesco WilderHill Clean Energy ETF (PBW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Invesco WilderHill Clean Energy ETF — how do they compare? Novo Nordisk A/S trades at $45.89 (market cap $207.31B), while Invesco WilderHill Clean Energy ETF trades at $34.96. The key difference: Novo Nordisk A/S pays a 3.76% dividend while Invesco WilderHill Clean Energy ETF pays none, and Invesco WilderHill Clean Energy ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | PBW | |
|---|---|---|
Market Cap | $207.31B | — |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $46.99 |
52-Week Low | $35.29 | $24.14 |
Enterprise Value | $222.02B | — |
Dividend Yield | 3.76% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.
Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.
PBW trades at $34.81, up 3.48% today, with a neutral technical signal and mixed moving averages. The clean energy ETF shows strength amid sector tailwinds from geopolitical tensions and data center demand, though it faces volatility from interest rate sensitivity. A dividend of $0.24 is scheduled for June 2026, but key valuation ratios like P/E and P/S are unavailable in the data.
The outlook hinges on clean energy adoption trends and Federal Reserve policy, with opportunities in global investment shifts but risks from rate cycles and oil price swings. Analyst sentiment is divided, reflecting the ETF's exposure to macroeconomic factors over company-specific fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →
